Someone mentioned on here before about Nemaura doing advertisement using Awesome Stocks.
They've just sent an email 'NASDAQ Trade Alert'. Doesn't provide any information but at least it is something just stated the last 2 RNS.
Hello!
Today, we have a new NASDAQ trade alert that could provide increased upside potential.
New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)
We first brought NMRD to your attention earlier this year. Following our alert in September, NMRD rallied upwards of 56%.
Over the past few weeks NMRD has consolidated below its 20 and 50 day moving averages.
This once again provides a potentially similar opportunity to the one in September.
In the event that NMRD breaks out above and stays above its 20 and 50 day moving averages, this could present increased upside potential.
NMRD has a 200 day moving average of 2.99, 52% above today’s close.
NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor.”
NMRD could be one of the few undervalued companies in its sector.
Some of NMRD’s closest competitors in the glucose monitoring sector have been reaching new all-time highs in 2018.
What’s interesting is that NMRD could have a better product than its competitors...
The current leading products in the market are invasive, requiring a needle like sensor to be inserted under the skin.
NMRD’s “patent-protected technology” on the other hand is “non-invasive” using an “adhesive skin-patch connected to a rechargeable transmitter”.
This could potentially be a game changer, and not only for people with diabetes…
According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”
Moreover, since our last alert, NMRD announced that it “Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®”
“Results indicate the alarm functionality can predict glucose level 5 minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy.”
“This development is expected to make sugarBEAT® more appealing to insulin users, a Total Addressable Market valued at $50Bn. CGM adoption amongst people with diabetes is minimal and growing rapidly, with the U.S. the largest single market, with an estimated 2.6% (630,000 users) of all diagnosed diabetics using CGM in 2018, representing annualized growth of 117%.”
Here is a summary from NMRD of it’s “Recent Highlights and Accomplishments”:
“SugarBEAT® reported positive interim data from clinic portion of study, planned for FDA submission.”
“Nemaura signed letter of intent for SugarBEAT® commercial launch in Qatar.”
“SugarBEAT® reported positive data for potential zero/reduced frequency of finger stick calibration.”
“Nemaura successfully developed predictive algorithms that will allow alarm functionality for sugarBEAT®.”
Dr. Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position to better support the expected commercial launch of sugarBEAT® in the United Kingdom in the coming weeks. Moreover, we anticipate achieving profitability in a significantly shorter term frame, as compared to other CGM providers, given the research and development costs we have incurred to date have been substantially lower, a trend we are confident will continue as we commercialize sugarBEAT®.”
Not only that, but NMRD recently announced:
Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar
“LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced that it has signed an exclusive license and distribution agreement with Al-Danah Medical Co. for the commercial launch of sugarBEAT® in Qatar in readiness for 2019 launch.
Qatar, has one of the world’s highest prevalence of diabetes, with 17% of the population diabetic and 23% pre-diabetic(1), and also has the world’s highest GDP per capita, and therefore represents a significant market for sugarBEAT®. Al-Danah Medical Company, part of the Almana Group, is a leading medical product distributor in Qatar, representing multiple global brands.
Current global CGM usage rates are low and growing rapidly. The U.S. is the largest single market, where CGM is being used by an estimated 2.6% (630,000 users) of all diagnosed diabetics in 2018, representing annualised growth of 117%. SugarBEAT® is expected to receive CE Mark approval shortly and launch next month in the United Kingdom, an addresable market for CGM estimated at $1.38B per annum. The global addressable market for CGM is estimated at $82B per annum.(2)”
NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.
If you agree, don’t miss this opportunity.
